Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-05-06Clinical Trial Update: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 trial evaluating the Ranibizumab Port Delivery System for sustained delivery in subfoveal neovascular age-related macular degenerati…
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept [Phase 4]
Phase 4 trial update exploring cytokine and visual outcomes in eyes treated with aflibercept for age-related macular degeneration and diabet…
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab [Phase 4]
Phase 4 trial exploring how cytokine changes relate to visual outcomes in eyes treated with ranibizumab for macular diseases.
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration [Phase 2]
Phase 2 trial assessing MT-0814 for age-related macular degeneration was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-03-25Clinical Trial Update: EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection [Phase 4]
Phase 4 trial evaluating genotypes using intravitreal aflibercept in macular degeneration has completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) [Phase 2]
Phase 2 open-label study of intravitreal ICON-1 in choroidal neovascularization due to age-related macular degeneration has been terminated …
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept [Phase 4]
Phase 4 trial update evaluating predictive factors and treatment changes among af Libercept regimens for central serous chorioretinopathy an…
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration [Phase 1, Phase 2]
Clinical trials update for RBM-007 in age-related macular degeneration (Phase 1/2) completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Visual Enhancement Device in Low Vision Patients [NA]
Clinical trial update for a visual enhancement device in low vision patients has terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2020-12-30Clinical Trial Update: BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration [Phase 4]
Phase 4 clinical trial update for BEOVU addressing dystrophy-related macular neovascular degeneration.
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD) [Phase 3]
Phase 3 trial assessing safety and clinical effectiveness of intravitreal bevacizumab (Lumiere) for wet age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase [Phase 3]
A Phase 3 clinical trial update on Lucentis (ranibizumab) assessing efficacy and safety in diabetic macular edema and related macular condit…
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF [Phase 2]
Phase 2 trial evaluating biweekly ranibizumab (0.5 mg) for exudative age-related macular degeneration with retinal edema unresponsive to ant…
-
EMA withdrawal · 2020-10-21EMA Application withdrawn: Rayoqta (abicipar pegol) — Allergan Pharmaceuticals International Limited
The EMA withdrew the application for Rayoqta (abicipar pegol) by Allergan for macular degeneration.
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium [Phase 4]
A Phase 4 extension study assessing the effect of Macugen on the corneal endothelium has completed, with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]
Phase 2 proof-of-concept trial of faricimab in choroidal neovascularization due to age-related macular degeneration has completed with resul…
-
CLINICAL_TRIALS trial_result · 2020-10-01Clinical Trial Update: A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） [Phase 3]
Phase 3 clinical trial comparing LY09004 with Eylea for wet age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2020-09-30Clinical Trial Update: A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy [Phase 3]
Phase 3 safety and efficacy study of Fovista in combination with Avastin or Eylea for age-related macular degeneration was terminated with r…
-
CLINICAL_TRIALS trial_result · 2020-09-24Clinical Trial Update: Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration [Phase 2]
Phase 2 trial evaluating intravitreal hI-con1 for choroidal neovascularization due to age-related macular degeneration has completed with po…
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration [Phase 1]
Phase 1 open-label study evaluating safety and tolerability of subcutaneous elamipretide in intermediate age-related macular degeneration ha…
-
EMA approval · 2020-09-16EMA Authorised: Visudyne (verteporfin) — CHEPLAPHARM Arzneimittel GmbH
EMA confirms authorisation of Visudyne (verteporfin) by CHEPLAPHARM Arzneimittel GmbH for indications related to degenerative myopia and mac…
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD [Phase 3]
Phase 3 trial update reporting on safety and ECG data collection for brolucizumab 6 mg intravitreal treatment in wet age-related macular deg…
-
CLINICAL_TRIALS trial_result · 2020-08-06Clinical Trial Update: Alpha Lipoic Acid in Geographic Atrophy [Phase 1, Phase 2]
Trial update for alpha lipoic acid in geographic atrophy as part of age-related macular degeneration; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-03Clinical Trial Update: A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial evaluating safety and treatment effect of abicipar pegol for neovascular age-related macular degeneration has completed with r…
-
CLINICAL_TRIALS trial_result · 2020-07-30Clinical Trial Update: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration [Phase 3]
Phase 3 trial update on safety and efficacy of abicipar pegol in neovascular age-related macular degeneration has completed with results pos…